Sign up for Table of Contents Alerts.

Email this page

Print this page

News

Dr. John C. Reed, Associate Editor of Cancer Biology and Therapy in the area of Apoptosis, is the Most Highly Cited Author in General Biomedicine from 1995-2005.

N/A

This is an open-access article

 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.

January 20, 2006—Chief Executive At Burnham Institute For Medical Research NamedAmong Top Doctors of the Decade

Dr. John C. Reed recognized as the most highly-cited researcher in the field of general biomedicine from 1995-2005 and 8th most highly-cited researcher in clinical medicine.

LA JOLLA, CA. Dr. John C. Reed, president and chief executive officer of the Burnham Institute for Medical Research, was listed among the Doctors of the Decade in the January/February 2006 issue of Science Watch, the bimonthly newsletter published by Thomson Scientific that tracks trends and performance in basic research. With 23,729 citations, Dr. Reed was ranked as the most cited author in the field of general biomedicine, a broad field of medicine that emphasizes principles of natural sciences including biochemistry and biology. Dr. Reed was also listed as the 8th most cited doctor overall in clinical medicine, which includes fields of epidemiology, cardiology and oncology in addition to biomedicine. The study was based on papers published and cited in journals monitored by Thomson Scientific between 1995 and 2005.

"One of the greatest honors as a scientist is to have your work cited by your peers," said John C. Reed, M.D., Ph.D., president and chief executive officer of the Burnham Institute for Medical Research. "I am grateful for the recognition but the real heroes are the dedicated scientists who work with me in our laboratory, my wonderful colleagues at Burnham with whom I collaborate extensively, and the efficient environment for research provided by our organization that allows scientists to get things done without bureaucratic obstacles."

The rankings solely reflect papers published in Thomson-indexed journals of clinical medicines. Dr. Reed has also compiled substantial citation records based on papers published in journals of molecular biology, genetics, biochemistry, and other fields not included in the Thomson study.

Despite his demanding role as chief executive of one of the world's most respected and productive non-profit biomedical research organizations, Dr. Reed remains an active scientist currently directing a laboratory of nearly 40 persons at the Burnham Institute. His research interests have focused primarily on cancer, but he has also made important contributions in the areas of AIDS, autoimmunity, stroke and other diseases. He has been a pioneer in delineating the fundamental mechanisms that regulate programmed cell death, a process by which cells in the body commit suicide through activation of a genetically controlled program known as apoptosis. As the author of over 600 peer-reviewed scientific articles on apoptosis, Dr. Reed has the distinction of having published more papers on programmed cell death during the past decade than any other scientist worldwide, according to the Institute for Scientific Information.

Dr. Reed is the inventor of the DNA-based drug Genasense™, currently undergoing Phase III clinical testing for patients with treatment-refractory cancers. His inventions have resulted in over 40 U.S. Patents or Patent applications and have spawned drug-discovery programs at several biopharmaceutical companies. Dr. Reed received his undergraduate education from the University of Virginia and earned his doctorate degrees at the Medical School of the University of Pennsylvania. Dr. Reed's residency training in Pathology & Laboratory Medicine was undertaken at the Hospital of the University of Pennsylvania, followed by post-doctoral training in Molecular Biology at the Wistar Institute in Philadelphia. Dr. Reed was an Assistant Professor in the Medical School at U. Penn from 1990-1992, and served as a director of the Laboratory for Molecular Diagnosis, performing DNA-based testing for clinical diagnosis at the university hospital. Dr. Reed joined the Burnham Institute in 1992 and was promoted to Scientific Director in 1995 before becoming President and CEO in 2002.

Dr. Reed's complete biosketch is available online at http://www.burnham.org/AboutTheInstitute/PresidentsMessage.asp.

Thomson Scientific is a business of The Thomson Corporation. Its information solutions assist professionals at every stage of research and development-from discovery to analysis to product development and distribution. Thomson scientific information solutions can be found at http://www.scientific.thomson.com.

About the Burnham Institute for Medical Research

The Burnham Institute for Medical Research, founded in 1976, is an independent not-for-profit biomedical research institution dedicated to advancing the frontiers of scientific knowledge and providing the foundation for tomorrow's medical therapies. The Institute is home to three major centers: the Cancer Center, the Del E. Webb Neuroscience and Aging Center, and the Infectious and Inflammatory Disease Center. Since 1981, the Institute's Cancer Center has been a member of the National Cancer Institute's prestigious Cancer Centers program. Discoveries by Burnham scientists have contributed to the development of new drugs for Alzheimer's disease, heart disease and several forms of cancer. Today the Institute employs over 725, including more than 550 scientists. The majority of the Institute's funding derives from federal sources, but private philanthropic support is essential to continuing bold and innovative research. For additional information about the Institute and ways to support the research efforts of the Institute, visit www.burnham.org.

This is an open-access article

 Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.